



STS Medical Receives FDA Regulatory Clearance

Misgav, Israel, 3 January 2018 – [STS Medical Ltd. \(“S.T.Stent”\)](#), a portfolio company of [The Trendlines Group Ltd. \(“Trendlines”\)](#) (SGX: 42T; OTCQX: TRNLY), announced today that it received regulatory clearance from the United States Food and Drug Administration (FDA) for its composite sinus stent.

Millions of people worldwide suffer from chronic sinusitis¹, an inflammation of the sinuses caused by infection or allergy and characterized by facial pain and pressure, nasal congestion, and headaches. When drug treatments are ineffective, Functional Endoscopic Sinus Surgery (FESS) is often performed to increase airflow within the nose and sinuses, improve drainage, and remove diseased tissue. However, up to 30% of these surgeries are unsuccessful due to scarring and recurrent inflammation that closes the nasal openings and requires revision surgery. S.T.Stent took on the challenge of developing a solution to dramatically reduce the number of revision surgeries performed.

S.T.Stent, founded in 2013, developed a removable stent to be placed after the FESS surgery -- that keeps the sinus cavity open for up to 28 days, long enough for the sinus tissue to heal. Stent removal is a minimally invasive procedure performed in the doctor’s office, without the need for anesthesia. The stent improves patient outcomes and reduces the probability of revision surgeries. In addition to chronic sinusitis, the stent can be used for nose job failures, chronic allergic rhinitis, and as a direct stenting as an alternative to sinuplasty.

“Following excellent results in our clinical trials performed on 30 patients earlier in 2017, we are extremely pleased to have received regulatory clearance from the FDA. This is a significant milestone for S.T.Stent which will allow us to market our product in the U.S.,” remarked Joseph Flomenbilt, Ph.D., CEO of S.T.Stent.

Chairman and CEO of The Trendlines Group, Steve Rhodes adds: “We are very proud of the progress that the S.T.Stent team has made towards bringing their truly innovative sinus stent to market. We look forward to following their progress in improving patient outcomes and reducing surgeries in a market seeking a solution to this common problem.”

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines’ shares are

¹ <https://www.cdc.gov/nchs/fastats/sinuses.htm>

traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

This press release has been prepared by The Trendlines Group Ltd. (the “Company”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”) for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)

Investor Contact Information:

Israel

Judith Kleinman, Director Investor Relations & Corporate Communications

The Trendlines Group

judith@trendlines.com

Tel: +972.72.260.7000

Singapore:

Reyna MEI Financial PR

reyna@financialpr.com.sg

Tel: +65.6438.2990